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A B S T R A C T
Drug-induced liver injury (DILI) is a common reason for drug withdrawal from the market. An important cause
of DILI is drug-induced cholestasis. One of the major players involved in drug-induced cholestasis is the bile salt
eﬄux pump (BSEP; ABCB11). Inhibition of BSEP by drugs potentially leads to cholestasis due to increased (toxic)
intrahepatic concentrations of bile acids with subsequent cell injury. In order to investigate the possibilities for in
silico prediction of cholestatic eﬀects of drugs, we developed a mechanistic biokinetic model for human liver bile
acid handling populated with human in vitro data. For this purpose we considered nine groups of bile acids in the
human bile acid pool, i.e. chenodeoxycholic acid, deoxycholic acid, the remaining unconjugated bile acids and
the glycine and taurine conjugates of each of the three groups. Michaelis-Menten kinetics of the human uptake
transporter Na+-taurocholate cotransporting polypeptide (NTCP; SLC10A1) and BSEP were measured using
NTCP-transduced HEK293 cells and membrane vesicles from BSEP-overexpressing HEK293 cells. For in vitro-in
vivo scaling, transporter abundance was determined by LC-MS/MS in these HEK293 cells and vesicles as well as
in human liver tissue. Other relevant human kinetic parameters were collected from literature, such as portal bile
acid levels and composition, bile acid synthesis and amidation rate. Additional empirical scaling was applied by
increasing the excretion rate with a factor 2.4 to reach near physiological steady-state intracellular bile acid
concentrations (80 μM) after exposure to portal vein bile acid levels. Simulations showed that intracellular bile
acid concentrations increase 1.7 fold in the presence of the BSEP inhibitors and cholestatic drugs cyclosporin A
or glibenclamide, at intrahepatic concentrations of 6.6 and 20 μM, respectively. This simpliﬁed model provides a
tool for a ﬁrst indication whether drugs at therapeutic concentrations might cause cholestasis by inhibiting BSEP.
1. Introduction
Drug-induced liver injury (DILI) is a major cause for drug with-
drawal from the market. The most common form is cholestatic DILI,
which can be distinguished into three phenotypes: cholestatic, hepa-
tocellular and mixed. One of the mechanisms of cholestatic DILI, as
proposed by Hofmann (1999) and Wagner et al. (2009), includes the
inhibition of canalicular hepatocellular bile acid (BA) excretion, re-
sulting in the accumulation of bile acids in the hepatocytes (Hofmann,
1999; Wagner et al., 2009). If toxic intracellular bile acid
concentrations are reached, this can lead to liver injury due to necrotic
and/or apoptotic cell death. Several transporters are involved in the
hepatocellular transport of bile acids. For uptake, the sodium-depen-
dent taurocholate transporter (NTCP, SLC10A1) and the organic anion
transporters (OATPs, SLCO) are assumed to be important players.
Multidrug resistance related proteins 3 and 4 (MRP3, ABCC3; MRP4,
ABCC4) and the organic solute transporter (OSTα/β; SLC51A/SLC51B)
are considered to be involved in sinusoidal eﬄux (Dawson et al., 2009),
which is low under normal physiological conditions. Most importantly,
the canalicular eﬄux transporter bile salt export pump (BSEP) seems to
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be the key player in the development of cholestatic DILI. This has been
summarized by Vinken et al. in an Adverse Outcome Pathway (AOP),
and further conﬁrmed by Woodhead et al. by sensitivity analysis of a
mechanistic model of cholestatic DILI (Vinken et al., 2013; Woodhead
et al., 2014).
To predict cholestatic eﬀects of newly developed drugs, animal
models are currently used. However, there is increasing awareness that
the current experimental animal models are not predictive for the
human clinical situation. This discrepancy can be due to species dif-
ferences in bile acid pool composition (García-Cañaveras et al., 2012;
Setchell et al., 1997), in individual bile acid concentrations and in
abundance and functionality of the transporters and enzymes involved
in bile acid handling, as well as in their susceptibility for interference
by the drug (Ulzurrun et al., 2013). Moreover, the animals used for drug
testing are genetically more uniform than the human patient population
and this can result in skewed results. Experimental human in vitro or ex
vivo models have been developed for testing cholestatic eﬀects of drugs,
such as sandwich and 3D spheroid cultures of human hepatocytes (Guo
et al., 2016; Hendriks et al., 2016), human liver slices (Vatakuti et al.,
2016a, 2016b) and human liver cell lines (HepaRG) (Hendriks et al.,
2016; Qiu et al., 2016). Next to these animal and human models, in
silicomodels can be applied to contribute to the preclinical prediction of
cholestasis in man.
An in silico model was recently described using DILIsym (Woodhead
et al., 2014), in which BA handling in rat and human was modelled in
the presence of a cholestatic drug (glibenclamide for rats and a theo-
retical cholestatic agent for humans). However, in this human model,
many of the mechanistic parameters on hepatocellular bile acid hand-
ling were not experimentally determined, but were optimized by re-
verse-modeling, taking the clinical BA proﬁle in humans as a starting
point. To date, molecular pharmacological data on bile acid handling
are not available in the literature. Kinetic parameters for the interaction
of human transporters (NTCP, BSEP and OATPs) and bile acids are ei-
ther not published with appropriate scaling factors or at best are
available only for taurocholate, which is a minor BA in humans. In
addition, Woodhead et al. showed that BSEP abundance is the most
important unknown kinetic parameter, that has a great inﬂuence on the
outcome of the BA concentration in the liver in the presence of a BSEP
inhibitor (Woodhead et al., 2014).
Here, we developed a bottom-up human biokinetic model of hepa-
tocyte bile acid handling. This model is based on existing and new
human in vitro kinetic data on hepatocellular bile acid handling, as well
as abundance data of key bile acid transporters. We aimed to predict the
eﬀect of competitive BSEP inhibitors on bile acid accumulation in the
human hepatocyte. As prototypical BSEP inhibiting drugs we used
glibenclamide and cyclosporin A. Both drugs have been associated with
cholestatic DILI and are inhibitors of BSEP (Byrne et al., 2002;
Goodman et al., 1987; Morgan et al., 2010; van Basten et al., 1992;
Varma et al., 2014).
2. Materials and Methods
2.1. Selection of Bile Acids Incorporated in Model
The following bile acids were selected to be included in the bioki-
netic model: deoxycholic acid (DCA), chenodeoxycholic acid (CDCA),
and their glycine- and taurine-amidated forms (GDCA, TDCA for DCA,
and GCDCA and TCDCA for CDCA). Together, they account for the
majority of the bile acids present within the human bile acid pool and
represent all three classes of bile acids of the human body: primary,
secondary and conjugated bile acids. Because kinetic data on trans-
porter-mediated handling of these bile acids were lacking, we de-
termined the aﬃnity (Km) and transport capacity (Vmax) and the ex-
pression of the transporters, as described below. The remaining bile
acids in the human bile acid pool were combined into 3 groups for
modeling purposes: unamidated, glycine amidated and taurine
amidated.
2.2. Development of the Mechanistic Biokinetic Model
In order to calculate the bile acid concentrations in the hepatocyte,
passive and active bile acid uptake and eﬄux were taken into account
as well as bile acid synthesis and amidation. Thus the intracellular
concentration over time was calculated for unamidated bile acids (Eq.
(1)) and amidated bile acids (Eq. (2)), in which C is the concentration, A
is the amount and Vc is the volume per million hepatocytes:
=
= +
+
dC /dt (dA /dt)/Vc
(active uptake rate passive uptake rate
BA synthesis rate–amidation rate–active efflux rate
–passive efflux rate)/Vc
cell,unamidated cell,unamidated
(1)
=
= +
+ −
−
dC /dt (dA /dt)/Vc
(active uptake rate passive uptake rate
amidation rate active efflux rate
passive efflux rate)/Vc
cell,amidated cell,unamidated
(2)
Unfortunately, human data to describe all of these parameters is far
from complete. Therefore, the following assumptions were made to
reduce the number of parameters and to include only the most relevant
available human data. The ﬁrst assumption is that only the ﬁrst peri-
portal hepatocytes that are exposed to the portal blood are modelled.
These cells are exposed to the highest bile acid concentration, as it is
well-known that this concentration decreases along the sinusoid
(Groothuis et al., 1982) and as such will give the ‘worst case scenario’
for bile acid exposure-related toxicity. Secondly, it is assumed that the
portal concentrations of bile acids do not change rapidly in response to
the intake of a cholestatic drug, which is acceptable due to the large size
of the bile acid pool and that strong eﬀects on the portal bile acid
concentration will only occur later on in the cholestatic process. In
addition, it is assumed that the synthesis rate of bile acids is constant
and that 5% of the bile acid pool is newly synthesized per day (Chiang,
2009). Regulation of bile acid synthesis could not be included in the
model as no quantitative data is available for this. The fourth as-
sumption is that the amidation rate is very high and that all bile acids
are instantaneously amidated (Falany et al., 1994). Hence, uptake and
synthesis rate of unamidated bile acids was assumed to be rate limiting.
Moreover it is anticipated that amidation is not saturable, given the
high enzymatic conversion capacity present in hepatocytes (Falany
et al., 1994). This would result in the absence of unamidated bile acids
intracellularly, which was indeed conﬁrmed by analysis of human in-
tracellular bile acid proﬁles (García-Cañaveras et al., 2012). Finally, it
is assumed that because of their hydrophilicity and resulting poor
membrane permeability, glycine and taurine amidated bile acids will
not undergo uptake or eﬄux by passive diﬀusion. This leads to the
following simpliﬁcation of the model in which each amidated bile acid
can now be described as:
=
= +
+ +
−
dC /dt (dA /dt)/Vc
(active uptake rate active uptake rate
passive uptake rate BA synthesis rate
active efflux rate )/Vc
cell cell
unamidated amidated
unamidated
amidated (3)
= + C
active uptake rate (NTCP)
(Vmax*C )/(Km )
unamidated
portal,unamidated portal,unamidated (4)
= ∗ +
active uptake rate (NTCP)
(Vmax C )/(Km C )
amidated
portal,amidated portal,amidated (5)
S. Notenboom et al. European Journal of Pharmaceutical Sciences 115 (2018) 175–184
176
= − ∗
passive uptake rate
C C passive diffusion rate constant
unamidated
portal,unamidated cell,unamidated (6)
= ∗ +
active efflux rate (BSEP)
(Vmax C )/(Km C )
amidated
cell,amidated cell,amidated (7)
Several transport proteins are involved in the uptake and eﬄux of
bile acids. To simplify the model, we only focused on the major bile acid
uptake transporter NTCP and the canalicular eﬄux transport BSEP. We
are aware that other uptake transporters such as OATP1B1, OATP2B1
and OATP1B3 are involved, as well as the canalicular eﬄux transporter
MRP2 and the sinusoidal eﬄux transporters MRP3, MRP4 and OSTα/β.
However, NTCP and BSEP are generally assumed to be the major
players and the kinetic parameters of the other transporters are not
available at this moment.
Our ﬁnal assumption includes competitive inhibition of bile acids
for both the uptake and eﬄux transporters using the adapted formula
for enzymes (Asante-Appiah and Chan, 1996; Martinez-Irujo et al.,
1998; Pocklington and Jeﬀery, 1969; Schäuble et al., 2013). In addi-
tion, the drugs we choose as model drugs, glibenclamide and cyclos-
porin A, are both competitive inhibitors of BSEP. For both transporters
the uptake/eﬄux rate for each of the individual bile acids is calculated
according to Eq. (8).
Vmaxx is the maximum transport rate, Sx is the substrate concentration,
Kmx is the concentration at which the transport rate is 50% of Vmaxx in
the absence of other bile acids and inhibitor, I is the concentration of
the inhibitor, Kmi is the concentration of the inhibitor at which the
transport rate is 50% reduced in the absence of other BAs, and x is one
of the bile acids 1–9.
1: CDCA.
2: GCDCA.
3: TCDCA.
4: DCA.
5: GDCA.
6: TDCA.
7: remaining bile acids.
8: remaining glycine amidated bile acids.
9: remaining taurine amidated bile acids.
I: competitive inhibitor (in this study glibenclamide or cyclosporin A).
The Km and Vmax values of the six bile acids, mentioned above,
were derived from uptake and eﬄux studies in HEK293 cells as de-
scribed below and were scaled to the human hepatocyte using the
abundance of the transporters in overexpressing cells and human liver.
However, as mentioned before, kinetic parameters for human trans-
porters (NTCP and BSEP) have not been published with appropriate
scaling. In literature and in our own data both the Km and Vmax were
rather similar within the group of unamidated, glycine amidated and
taurine amidated. Therefore, we took the average of the values ob-
tained in each of these three groups and used these values for the un-
amidated, glycine amidated and taurine amidated remaining bile acid
groups (see Table 3). The transport rates were then calculated using Eq.
(4).
As mentioned above it was assumed that 5% of the total bile acid
pool is newly synthesized per day. In addition, it was also assumed that
both primary and secondary bile acids were synthesized in the hepa-
tocytes and that bile acids were synthesized in the same ratio as they
appear in blood (Scherer et al., 2009). In addition, it was assumed that
all bile acids were amidated with glycine and taurine instantaneously
relative to the ratio of these amidated bile acids present in the hepa-
tocyte, i.e. 70% and 30% respectively (García-Cañaveras et al., 2012).
The bile acid synthesis rate was scaled to a million human hepatocytes.
Ho et al. described a bile acid pool of 0.136 mmol/kg body weight (Ho
et al., 1980) in a 70 kg person with 1.5 kg of liver. This results in a bile
acid synthesis rate of 0.22 pmol bile acid/min/g liver, which is
1.8 pmol bile acids/min/106 hepatocytes, assuming a hepatocellularity
of 122 × 106·hepatocytes per gram liver (Arias, 1988; Wilson et al.,
2003; Sohlenius-Sternbeck, 2006)(Arias, 1988; Sohlenius-Sternbeck,
2006; Wilson et al., 2003). For each bile acid the synthesis rate was
calculated proportional to their fractional blood concentration (see
Table 1). These values were all included in Eq. (3), and the intracellular
concentration of each of the 9 groups of bile acids and their total
concentration were simulated using Berkeley-Madonna (version 8.3.18,
University of California; http://www.berkeleymadonna.com), as-
suming a hepatocyte volume of 0.01 ml/106 hepatocytes. The details of
the script are given in the supplementary data.
2.3. Culture and Transduction of HEK293 Cells
HEK293 cells used for transduction with either NTCP or BSEP were
cultured under standard conditions at 37 °C and 5% CO2. Cells were
cultured using Dulbecco's Modiﬁed Eagle Medium (DMEM)
(ThermoFisher scientiﬁc) supplemented with 10% Fetal Calf Serum
(FCS) (Greiner bio-one). HEK293 cells were seeded in 96-well plates
coated with Poly-D-Lysine (Corning) and incubated for 24 h at 37 °C and
5% CO2. Then, transduction was performed by adding 30 μl of bacu-
lovirus-containing solution, encoding NTCP, BSEP, or Enhanced Yellow
Fluorescent Protein (EYFP) as a negative control. Following addition of
the virus, sodium butyrate was added to a ﬁnal concentration of
5.0 mM in order to enhance transcription and ultimate transporter
protein expression. After another 72 h of incubation at 37 °C and 5%
CO2 (uptake experiments were performed with cells expressing NTCP or
EYFP and vesicles were prepared from cells transduced with BSEP or
EYFP).
2.4. Production of BSEP Membrane Vesicles
Vesicles were obtained following transduction of HEK293 cells with
baculovirus encoding BSEP or EYFP as a negative control. Following the
incubation for 72 h at 37 °C and 5% CO2 as described above, the cells
were harvested and were then lysed and fused into membrane vesicles
Table 1
Bile acid synthesis rates.
Synthesis rate (μmol/min/106 hepatocytes)
CDCA 0.14 × 10−6
GCDCA 0.68 × 10−6
TCDCA 0.08 × 10−6
DCA 0.19 × 10−6
GDCA 0.15 × 10−6
TDCA 0.02 × 10−6
RBA 0.22 × 10−6
GRBA 0.28 × 10−6
TRBA 0.05 × 10−6
RBA (Remaining bile acids), GRBA (Remaining glycine-amidated bile acids), TRBA
(Remaining taurine-amidated bile acids).
=
+ + + + + + + + + +
v Vmax *
1
x
Sx
Kmx
S
Km
S
Km
S
Km
S
Km
S
Km
S
Km
S
Km
S
Km
S
Km
I
Kmi
x 1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9 (8)
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using a LV1 Low Volume High Shear microﬂuidizer (Microﬂuidics,
Westwood, MA), followed by centrifugation at 4000g at 4 °C for 20 min
and subsequent centrifugation of the resulting supernatant at 25,000g
at 4 °C for 90 min in order to obtain the membrane fractions.
Preparations, consisting of a 1:1 ratio of inside-out and right-side-out
vesicles, were then resuspended in Tris-Sucrose (TS) buﬀer (10 mM
Tris, 250 mM Sucrose, pH 7.4) and stored at −80 °C until further use.
2.5. Transporter Kinetics
In order to determine the Km and Vmax of bile acid transport by
NTCP, HEK293 cells transduced with NTCP or EYFP (control) were
used. Cells (10,000 cells/well) were cultured in poly-D-lysine coated 96-
well plates. After 24 h, cells and were washed with 37 °C HBSS-HEPES
pH 7.4 buﬀer, before incubation with increasing concentrations
(0–50 μM) of one of the bile acids of interest in HBSS-HEPES pH 7.4.
After 1 min of incubation at 37 °C, the plate was inverted and im-
mediately washed with ice-cold HBSS-HEPES pH 7.4 containing 0.5%
Bovine Serum Albumin in order to bind excess bile acids. Then, the cells
were washed twice with ice-cold HBSS-HEPES pH 7.4 and after removal
of the washing buﬀer, the plates containing the cells were stored at
−20 °C until subsequent LC-MS/MS analysis of intracellular bile acid
concentrations, as described below.
The Km and Vmax of ATP-dependent BSEP transport of the bile
acids of interest were determined using membrane vesicles containing
BSEP or EYFP (control). Vesicles were thawed and transferred to a 96-
well plate, containing 25 μl of a mix containing TS buﬀer, supple-
mented with 10 mM MgCl2, 4.0 mM ATP pH 7.4 and increasing con-
centrations (0–50 μM) of the bile acid of interest. Following incubation
of the plate at 37 °C for 1 min, the plate was placed on ice and 150 μl of
ice-cold TS buﬀer was added to stop the reaction. The samples were
then transferred to a 96 well ﬁlter plate (Millipore) pre-incubated with
TS buﬀer. The ﬁlter membrane was then washed twice with ice-cold TS
buﬀer. Subsequently, the ﬁlters were punched out of the plate and used
for LC-MS/MS mediated measurement of intravesicular bile acid con-
centrations as described below. In parallel experiments, vesicles derived
from EYFP transduced cells were used to determine the passive trans-
port rate of the various bile acids.
2.6. LC-MS/MS Analysis of Bile Acids
Bile acid concentrations were determined with LC-MS/MS, using an
Acquity UPLC (Waters, Milford, MA, USA) coupled to a Xevo TQ-S
(Waters) triple quadrupole mass spectrometer. The compounds were
separated using a Zorbax Eclipse Plus C18 analytical column (Rapid
Resolution HD 1.8 μm; 50 × 2.1 mm, Agilent, USA). The elution gra-
dient was as follows: 0 min 70%A/30% B, 2–2.5 min 20%A/80% B, and
2.6–4.0 min 70%A/30% B. Solvent A consisted of 0.1% formic acid in
water and Solvent B consisted of 0.1% formic acid in acetonitrile. The
column temperature was set at 40 °C, and the ﬂow rate was 500 μl/min.
The eﬄuent from the UPLC was passed directly into the electrospray
ion source. Negative electrospray ionization was achieved using ni-
trogen as a desolvation gas with the ionization voltage set at 3.0 kV.
The source temperature was set at 500 °C and argon was used as col-
lision gas. Detection of the bile acids was based on isolation of the
deprotonated molecular ion, [M - H]− and subsequent MS/MS frag-
mentations and multi reaction monitoring (MRM). The following MRM
transitions were used: for TDCA and TCDCA m/z 498.1(parent ion) to
m/z 498.1 and 80.2 (both product ions), for GDCA m/z 448.3(parent
ion) to m/z 448.3 and 74.0 (both product ions), for GCDCA m/z 448.3
(parent ion) to m/z 386.8 and 74.0 (both product ions), for DCA m/z
391.2 (parent ion) to m/z 391.2 and 345.0 (both product ions), for
CDCA m/z 391.2 (parent ion) to m/z 391.2 and 373.2 (both product
ions). DCA was used as internal standard for TDCA, TCDCA, GDCA and
GCDCA, whereas GDCA was used as an internal standard for DCA and
CDCA. For each of the analyzed bile acids, calibration curves were
constructed in the relevant matrix for ultimate quantiﬁcation of the
amount of bile acid.
2.7. Simulation of Intrahepatic Glibenclamide and Cyclosporin A
Concentrations
Physiologically-based pharmacokinetics (PBPK) models were used
to predict the portal vein and intrahepatic concentrations of glib-
enclamide and cyclosporin A. These concentrations were generated
using Simcyp® Simulator version 13.2. For glibenclamide, a full PBPK
model published by Varma et al. (2014) was used in a 7-day simulation
with an oral dose of 7.5 mg given every 12 h to 50 healthy volunteers.
This is the maximum recommended dose for glibenclamide. For cy-
closporin A, a minimal PBPK model present within the Simcyp® Simu-
lator was transformed into a full PBPK model by incorporating an in-
travenous clearance value and subsequent scaling of the volume of
distribution to values reported in literature. The simulation was per-
formed for 50 healthy volunteers taking 525 mg of cyclosporin A every
12 h for 7 days. This is the recommended maximum dose of 15 mg/kg
for prophylaxis of solid organ transplant rejection during the ﬁrst
1–2 weeks after transplantation for a 70 kg human being.
2.8. BSEP and NTCP Abundance Measurements
Abundance measurements were performed as described previously
(Van De Steeg et al., 2013). Protein abundance of BSEP and NTCP in the
plasma membrane was measured in transduced HEK293 cells (over-
expressing BSEP or NTCP) and in a pooled human liver sample origi-
nating from three individual donors. Human liver samples were ob-
tained from patients undergoing partial hepatectomy for liver
metastasis of colorectal carcinoma, as described before (de Graaf et al.,
2010). The absolute transporter protein abundance was corrected for
the abundance of the membrane protein ATP1A1, used as an internal
standard. The Vmax values of bile acid transport by BSEP and NTCP
were used to calculate bile acid ﬂuxes (according to the Eqs. (3)–(5) and
(7) outlined above), which is by deﬁnition dependent on the expression
of the transporters at the plasma membrane. In order to scale from in
vitro to in vivo human liver, the Vmax values from the in vitro systems
were expressed per pmol transport protein and subsequently scaled to
the amount of transport protein present in the human liver (see
Table 3). Similarly the passive diﬀusion rate constant was expressed per
μg plasma membrane protein and subsequently scaled to the amount of
plasma membrane protein in the human liver. In addition this rate
constant was corrected by 1/6 assuming that only 1/6 of the plasma
membrane in the liver will be on the sinusoidal side where the passive
transport takes place.
3. Results
3.1. Kinetic Parameters of Bile Acid Transport by NTCP and BSEP
The results of the uptake of bile acids by HEK293 cells over-
expressing NTCP are shown in Fig. 1. Km values for these 6 bile acids
were rather similar and ranged from 4.9–10 μM. However, there was a
clear diﬀerence in Vmax between the unconjugated and conjugated bile
acids, with the unconjugated showing a lower maximal transport rate
(40–50 pmol/mg protein/min) than the conjugated (1200–1700 pmol/
mg protein/min).
For BSEP transport studies, we used vesicles isolated from HEK293
cells over-expressing BSEP and compared the data to those obtained
with control vesicles containing EYFP. The results from these studies
are presented in Fig. 2. Whereas TDCA, GCDCA and TCDCA showed
similar Km values between 4.1 and 7.4 μM, we detected a relatively
lower aﬃnity of GDCA (Km= 19 μM). We did not determine Mi-
chaelis-Menten kinetics for the two unconjugated bile acids included in
the present study, as one of the key assumptions was instant amidation
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of unconjugated bile acids upon uptake by the hepatocyte, thus ex-
cluding their biliary excretion.
3.2. Simulated Intrahepatic Concentrations of Glibenclamide and
Cyclosporin A
In order to simulate the eﬀect of cholestatic drugs in the model, we
selected two known cholestatic compounds (glibenclamide and cy-
closporin A) and we used the Simcyp simulator to predict their in-
trahepatic concentrations upon reaching steady-state levels under
commonly applied dosing regimen. In short, the predicted intrahepatic
concentration for glibenclamide at a dosing regimen of 7.5 mg twice
daily was 0,02 uM. The total predicted steady-state concentration in the
liver after cyclosporin A administration (525 mg bid) was 6.6 μM. As no
good estimate of intracellular unbound concentrations was available for
CsA, we ran subsequent simulations in the biokinetic bile acid handling
model for the worst case scenario, i.e. assuming all cyclosporin A within
the hepatocyte to be unbound and available for BSEP inhibition.
3.3. Abundance Measurement of NTCP and BSEP
In the HEK293 cells transduced with NTCP, the abundance of NTCP
was 156 fmol/μg plasma membrane protein. The abundance of trans-
port protein in vesicles of BSEP-overexpressing HEK293 cells was
59.4 fmol/μg plasma membrane protein. In the human liver sample the
abundances were 5.9 fmol/μg plasma membrane protein and 6.7 fmol/
μg plasma membrane protein, respectively (Table 2).
3.4. Biokinetic Mechanistic Model
The biokinetic model used after simpliﬁcation as described in the
methods section, is represented in Fig. 3.In order to parameterize our
biokinetic model with the results from the HEK293 cellular over-
expression studies, a correction is needed for the diﬀerent abundances
Fig. 1. Initial uptake rates of the bile acids CDCA, DCA and their glycine (GCDCA and GDCA) and taurine (TCDCA and TDCA) conjugates by HEK293 cells overexpressing NTCP. The Km
and Vmax calculated from these data are presented in the inserts (data represent the mean ± SEM of n= 3–4 independent experiments).
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of the transporters in the cell systems and the human liver. This was
achieved by scaling the NTCP and BSEP expression in the diﬀerent
systems to an average expression in human liver (Table 2). For the
abundance of NTCP in human liver 5.9 fmol/μg plasma membrane
protein and of BSEP 6.7 fmol/μg plasma membrane protein was found
(Table 2), resulting in scaling factors of 4.01 × 10−7 and 7.93 × 10−7.
The scaled abundance data were used to calculate the Vmax in human
liver for the individual bile acid groups. For this purpose, Vmax values
from the in vitro systems were expressed per pmol transport protein and
subsequently scaled to the amount of transport protein present in the
human liver. HEK293 cells overexpressing NTCP contained 1.9 μg
plasma membrane protein/mg total protein. HEK293 vesicles
overexpressing BSEP contained 60 μg crude membrane protein/mg
total protein, resulting in 32 μg plasma membrane protein/mg total
protein (unpublished data). For the BSEP expressing membrane vesicles
it was assumed that 50% were oriented inside-out and 50% rightside-
out. This implies that only 50% of the expressed BSEP protein is func-
tionally involved in bile acid uptake by the vesicles. The pooled liver
contained 4.2 μg plasma membrane protein per million cells assuming
122 × 106·hepatocytes per gram liver (Arias, 1988; Wilson et al., 2003;
Sohlenius-Sternbeck, 2006).
Table 3 shows the Km and Vmax values for human liver used in the
biokinetic model (obtained in this study) as well as the portal con-
centrations of the respective bile acids used for modeling (Scherer et al.,
2009; Vatakuti et al., 2016a).
Passive transport was determined by the rate observed in the EYFP-
transduced HEK293 cells, assuming that this transport was passive. A
slight overestimation of transport rate cannot be excluded due to non-
speciﬁc binding. However this will not be of major inﬂuence on the
model outcome as the passive transport rate is low, between 0.37 and
0.53 pmol/min/106hepatocytes/μM, as described in Table 3.
3.5. Biokinetic Mechanistic Model for Bile Acid Handling
All values used to parameterize the biokinetic model are given in
Table 3. When the values for Km and Vmax of the nine bile acids as well
as the data for bile acid synthesis were incorporated, the model did not
reach a physiological steady-state concentration of bile acids in the
hepatocyte as depicted in Fig. 4 A, indicating missing or inadequate
data. As can be seen in Fig. 4B, the eﬄux system is saturated rapidly
due to the fast increase of bile acid concentration and operates at
maximum velocity, leading to a continuous increase in intracellular bile
acid concentrations in time. Apparently, the uptake rate of bile acids
exceeds the excretion rate, even under Vmax conditions of BSEP.
However, by additional empirical adjustment of BSEP abundance,
based on the assumption that our model likely reﬂects an
Fig. 2. Initial uptake rate of the amidated bile acids by vesicles from HEK293 overexpressing BSEP. The values calculated for Km and Vmax are presented in the inserts. (n = 3).
Table 2
Abundance of NTCP and BSEP in transduced HEK293 cells/vesicles scaled to human liver.
HEK293-NTCP
cells
HEK293-BSEP
vesicles
Pooled human
liver
Transporter abundance
NTCP abundance
(fmol/μg plasma
membrane
protein)
156 < LLD 5.9
BSEP abundance
(fmol/μg plasma
membrane
protein)
< LLD 119a 6.7
Scaling
Plasma membrane
protein
1.90 μg PMP/mg
protein
31.7 μg PMP/mg
protein
4.18b μg PMP/
106 hepatocytes
Scaling factor 4.01 × 10−7 7.93 × 10−7 1
< LLD (below limit of detection), PMP (plasma membrane protein).
a Assuming 50% inside out vesicles, i.e. only 59.4 fmol functional BSEP/μg plasma
membrane protein.
b Assuming 122 × 106 hepatocytes per g liver (Arias, 1988; Wilson et al., 2003;
Sohlenius-Sternbeck, 2006).
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underestimation of the BSEP abundance, we found that increasing the
abundance by 2.4 times, resulted in near physiological intracellular bile
acid concentrations after exposure to physiological portal vein bile acid
levels (Fig. 4C, D).
3.6. Eﬀect of the Presence of Cholestatic Drugs on the Intrahepatic Bile Acid
Concentration
Upon intrahepatic exposure of 6.6 μM cyclosporin A, an increase in
intracellular bile acid concentration is predicted. This results in a new
steady state with a 1.7 fold increase in hepatocyte bile acid con-
centration (Fig. 5A, B). However, simulation of exposure to the ther-
apeutic liver concentration of glibenclamide (0.02 μM) did not result in
an increase in bile acid concentration (Fig. 5C). We used the model to
ﬁnd a concentration of glibenclamide that would results in a similar
increase in bile acid concentration as 6.6 μM cyclosporin A. This ap-
peared to be a concentration of 20 μM, which is 1000-fold higher than
the predicted therapeutic glibenclamide concentration (Fig. 5D).
4. Discussion
We developed a mechanistic biokinetic model of hepatocyte bile
acid handling based on human in vitro data (Fig. 3), which simulates
intrahepatic bile acid concentrations in the absence and presence of
cholestatic drugs. This model can be used for prediction of cholestatic
potential of drugs during drug development. We measured and included
kinetic data of two selected bile acids and their glycine and taurine
conjugates for the two most important human bile acid transporters
(NTCP and BSEP) and the remaining bile acids were taken as one group
as well as their glycine and taurine conjugates. The abundance of NTCP
and BSEP was measured in our in vitro HEK293 cell models and in
human liver for scaling purposes, and we used data obtained from lit-
erature on bile acid synthesis and amidation. (Table 1).
An essential step for development of the model described here was
the generation of kinetic data for the interaction of bile acids with NTCP
and BSEP. The only literature data available for BSEP are Km values for
TCDCA, TDCA, and GCDCA, which range between 4.2 and 12.5, 34.4,
and 1.7–7.5, respectively (Hayashi et al., 2005; Kis et al., 2009;
Yamaguchi et al., 2009). The Km values obtained for TCDCA and
GCDCA in the present study are similar to these previously reported
values. However, the Km we determined for TDCA was lower than
published by Kis et al., which could be accounted for by the use of
diﬀerent model systems. For the other three bile acids in our model, we
have generated kinetic data on BSEP-mediated transport. To our
knowledge, this is the ﬁrst time that transporter kinetics have been
determined for the interaction of such an extensive set of bile acids
(including DCA and CDCA) with the two major bile acid transporters,
BSEP and NTCP. Interestingly, the four conjugated bile acids studied
here show rather similar aﬃnities and maximum transport rates for
each of the transporters, but these values are clearly diﬀerent from
those of the two unconjugated bile acids. They appear to be transported
by both transporters at a much lower rate than their conjugated
counterparts and are mainly taken up by passive diﬀusion as measured
by the uptake rate in mock-transduced HEK293 cells, lacking a bile acid
Fig. 3. Schematic overview of the bioki-
netic mechanistic model to determine the
bile acid concentration in the hepatocyte.
Table 3
Michaelis-Menten kinetics for NTCP, BSEP and passive transport in the human hepatocyte scaled for abundance.
NTCP BSEP Passive diﬀusion rate constant
Bile acids Portal conc (μM) Km
(μM)
Vmax (pmol/min/106 hepatocytes) Km
(μM)
Vmax (pmol/min/106 hepatocytes/)
(pmol/min/106 hepatocytes/μM)
CDCA 4.5 4.9 ± 2.3 21 ± 6 0.45 ± 0.09
GCDCA 22.6 10 ± 2.0 510 ± 120 4.1 ± 0.4 91 ± 47
TCDCA 2.8 5.7 ± 0.3 630 ± 50 3.7 ± 1.2 148 ± 21
DCA 6.4 5.0 ± 2.3 16 ± 12 0.48 ± 0.10
GDCA 5.0 8.4 ± 0.7 600 ± 50 19 ± 2.6 131 ± 3.0
TDCA 0.6 10 ± 0.6 684 ± 60 7.4 ± 1.5 154 ± 22
RBA 7.3 4.9* 18* 0.46*
GRBA 9.1 9.2* 561* 11.5* 111*
TRBA 1.8 7.9* 656* 5.5* 151*
n = 3–4, *Estimated as described in methods.
Abbreviations: RBA (Remaining bile acids), GRBA (Remaining glycine-amidated bile acids), TRBA (Remaining taurine-amidated bile acids).
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uptake transporter. This can be explained by their higher lipophilicity
(LogP > 2.5). Therefore, we included parameters for passive uptake in
our model (Table 3). We assumed that bile acid amidation is very rapid
and not saturated under physiological conditions with a Km around
1 mM for taurine conjugation and 6 mM for glycine conjugation (Falany
et al., 1994). Both values are much higher than the intracellular bile
acid concentration; therefore excretion of unconjugated bile acids from
the liver will play only a minor role and can be neglected in our model.
The unexpected accumulation of bile acids in the simulations where
the experimentally found BSEP abundance was used could be caused by
an overestimation of uptake rate or underestimation of excretion rate.
Scaling of BSEP abundance was adapted so that it resulted in near
physiological intracellular bile acid concentrations under normal
exposure to portal vein bile acid levels. The relatively small scaling
factor of 2.4 needed to reach a physiological total bile acid con-
centration in the hepatocyte shows that the model is very sensitive to
BSEP abundance, as was also predicted by the DILIsym simulations
(Woodhead et al., 2014). As we only measured BSEP abundance in a
pooled sample of 3 human livers, no conclusion can be drawn on the
variation of its expression in human livers. However, based on the data
of Ji et al., it is expected that the expression of BSEP is subject to> 2-
fold variation. They analyzed 15 human livers and found BSEP ex-
pressions between 3 and 7 fmol/ug membrane protein (Li et al., 2009).
The expression of 7 fmol/ug membrane protein found in our pooled
liver sample is within this range. In addition to variations in abundance,
variability in BSEP functional activity could contribute to diﬀerences in
Fig. 4. The predicted intracellular concentrations (A) and canalicular eﬄux rates (B) of bile acids in the human hepatocyte following exposure to 60 μM bile acids on the portal side. The
black dotted line in 3B represents the uptake rate of total bile acids (TBA) by NTCP, showing that uptake > eﬄux (B). After ﬁtting the model to intracellular bile acid concentrations
within the physiological range as measured by Starokozhko et al. (unpublished data), the model shows the adjusted predicted intracellular concentrations (C) and canalicular eﬄux rates
(D) of bile acids in the human hepatocyte following 60 μM bile acids exposure on the portal side.
Fig. 5. The predicted intracellular concentrations of bile acids in the human hepatocyte following exposure to 60 μM bile acids on the portal side in the absence (A) and presence of
6.6 μM cyclosporin A (B), 0.02 μM glibenclamide (C) and 20 μM glibenclamide (D).
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the population as a result of polymorphisms (Chen et al., 2016) or
subcellular distribution in membrane vesicles (Kubitz et al., 2004).
Further studies with more human liver samples and more sophisticated
separation of canalicular membranes from other intracellular mem-
branes/vesicles may provide more insight into this scaling factor. The
high sensitivity of intracellular bile acid concentration to BSEP activity
as shown in our model and in the DILIsym model can explain the large
variation in sensitivity for cholestatic drug eﬀects in the human popu-
lation.
The value found for NTCP of 5.9 fmol/μg plasma membrane protein
might have been an overestimation of active transporter as it is higher
than found by others (Qiu et al., 2013; Wang et al., 2015) and it has
been reported that the transporter can be also found in submembrane
vesicles (Sommerfeld et al., 2015; Webster et al., 2002). The role of
OATPs in the uptake of bile acids was assumed to be low, but this
should be incorporated in a future version of the model. A more likely
explanation of the accumulation of bile acids might be the presence of
other biliary eﬄux transporters, such as MRP2 at the canalicular
membrane. However, as MRP2 has always been described to transport
sulfate and glucuronide conjugates, which constitute only a very small
fraction of the bile acid pool, its contribution to biliary bile acid ex-
cretion rate might be limited. Nevertheless this fraction includes sul-
fated LCA, which is supposed to be toxic to the hepatocyte. Also MRP3,
MRP4 and OSTα/β on the basolateral membrane might be involved in
sinusoidal excretion, especially under cholestatic conditions, as the
expression of MRP3 and 4 are low under normal conditions but are
upregulated during cholestasis (Gradhand et al., 2008; Vinken et al.,
2013). Adding these eﬄux transporters to the model might improve the
simulations, but quantitative data is lacking to date. In addition, our
model does not take into account sinusoidal excretion and reuptake of
bile acids in the hepatocytes downstream along the sinusoids. As this
sinusoidal excretion is low, additional availability of bile acids for up-
take is also limited, which results in lower portal bile acid concentra-
tions down the sinusoids. It should also be noticed that the BSEP
abundance measured in this study is an average of all hepatocytes,
while it was shown that bile acid excretion is lower in perivenous cells
than periportal cells if exposed to the same bile acid concentration.
(Groothuis et al., 1982).
As already indicated above, bile acid amidation was considered to
be immediate and complete, which is supported by the high Km values
(1-6 mM) found for this metabolism (Falany et al., 1994). However it
cannot be excluded that under cholestatic conditions amidation is sa-
turated or undergoes product inhibition, which should be subject of
future investigations.
The synthesis rate of new bile acids was based on the general as-
sumption that synthesis equals bile acid loss, which is estimated to be
5% of the bile acid pool per day. Although it is generally known that
proteins involved in bile acid synthesis and transport are regulated via
FXR, DILIsym results indicated that this regulatory pathway does not
have a substantial eﬀect on the intracellular concentration of bile acids
(Woodhead et al., 2014). Therefore, and because experimental quan-
titative data are lacking, we did not incorporate any regulation in our
model.
Subsequently, we simulated the eﬀect of the presence of two known
cholestatic drugs, cyclosporin A and glibenclamide, which resulted in
an increase in intracellular bile acid concentrations. For cyclosporin A
we used the maximal intrahepatic concentration (6.6 μM) after an oral
dose of 525 mg twice daily (15 mg/kg/day), as estimated with the
Simcyp simulator. This induced a 1.75-fold increase of the bile acid
concentration to 140 μM. The question remains how much bile acid
concentrations should rise to result in cholestatic liver injury. Recent
studies with rat precision cut liver slices (PCLS) (Starokozhko et al.,
2017) showed that a 50% decrease in viability (measured by ATP
content) was observed at a cyclosporin A concentration that raised the
bile acid content in the slices by a factor of 2.5. Studies with human
PCLS are ongoing.
For glibenclamide an intrahepatic concentration of 0.02 μM was
predicted using the Simcyp simulator for a therapeutic dose of 15 mg/
day. In our biokinetc model this concentration did not result in changes
in bile acid concentrations, which can be explained by the high Km of
glibenclamide for BSEP (27.5 μM)(Byrne et al., 2002). This is in line
with clinical ﬁndings that at therapeutic doses of 7.5 mg bid glib-
enclamide-induced cholestasis is an idiosyncratic phenomenon, occur-
ring only in a minority of patients. At a 1000-fold higher concentration,
an increase in bile acid levels in the hepatocyte was predicted, which is
well in line with the DILIsym data on rats with very high plasma con-
centrations of glibenclamide (> 20 μM) that displayed increased
plasma concentrations of bile acids (Woodhead et al., 2014). Moreover,
a 2.4-fold increase in liver bile acid concentration was found in rat PCLS
exposed to 180 μM (=89 μg/ml) glibenclamide, but not at lower con-
centrations (Starokozhko et al., 2017). These data indicate that glib-
enclamide-induced cholestasis can be due to BSEP inhibition only in
patients with a genetic variant or low abundance of BSEP. Alter-
natively, it cannot be excluded that glibenclamide induces cholestasis
by an as yet unknown mechanism (Starokozhko et al., 2017).
In summary, the mechanistic biokinetic model presented here is
able to provide a ﬁrst indication on whether drugs at therapeutic con-
centrations might cause cholestasis by inhibiting BSEP. Next to an in-
hibitory constant of a drug for BSEP, a PBPK model to simulate its in-
trahepatic concentration will be needed to predict whether this
simulated cholestatic concentration will actually occur at the intended
therapeutic plasma concentrations. This would enable performing in-
itial risk assessments based on human in vitro data only, thereby serving
as a replacement of animal experiments.
In the future our model can be optimized and reﬁned by adding
more data on speciﬁc bile acids, especially the sulfation and glucur-
onidation rates of the toxic lithocholic acid. In addition more data are
needed on bile acid transport by OATPs, MRP3, MRP4 and OST α/β,
saturation of amidation, regulation of transporter expression and
synthesis rate, as well as protein binding of the bile acids and drugs.
Realizing all these shortcomings, the predictive value of the model for
cyclosporine A and glibenclamide appeared remarkably well, indicating
that the most important parameters have been included.
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